naion semaglutide news may increase risk for nonarteritic anterior ischemic optic neuropathy Semaglutide Doubles Risk for NAION

As the Guardians Adam Gabbatt showed in their investigation, its shockingly easy to purchase peptides on the online gray market thats buying goods that are authentic but not approved or regulated

SURMOUNT-5, published in NEJM, compared tirzepatide against semaglutide head-to-head over 72 weeks, reporting 20.2% versus 13.7% the first rigorous direct evidence that dual agonism outperforms mono-agonism in the same population under the same protocol

Sustained, significant weight loss Studies show that people using brand-name tirzepatide for the long term tend to lose a significant amount of weight and keep it off

We cant say that GLP-1s are actually causing these symptoms, says Neil K

4SURMOUNT-1 (Tirzepatide/Mounjaro) NEJM 2022 Jastreboff AM, et al